2-(2-aminopropoxy)-1,3-dimethylbenzene

• ChemBase编号: 263
• 分子式: C11H17NO
• 平均质量: 179.25878
• 单一同位素质量: 179.13101417
• SMILES: O(CC(N)C)c1c(cccc1C)C
• Canonical SMILES: CC(COc1c(C)cccc1C)N
• InChI: InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3
• InChIKey: VLPIATFUUWWMKC-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-(2-aminopropoxy)-1,3-dimethylbenzene
• IUPAC传统名: mexiletine
• 商标名: Mexitil
• 别名: 2-(2-aminopropoxy)-1,3-dimethylbenzene; Mexiletina [INN-Spanish]; Mexiletine HCL; Mexiletinum [INN-Latin]; Mexilitine; Mexiletine

登记号

• CAS号: 31828-71-4
• MDL号: MFCD00792471
• PubChem SID: 46505491; 160963726
• PubChem CID: 4178
• CHEBI ID: 6916
• ATC码: C01BB02
• CHEMBL: 558
• Chemspider ID: 4034
• DrugBank ID: DB00379
• IUPHAR配体索引: 2629
• KEGG ID: D08215
• 美国药典/FDA物质标识码: 1U511HHV4Z
• 维基百科标题: Mexiletine
• Medline Plus: a607064

理论计算性质

JChem

• 质子受体: 2
• 质子供体: 1
• LogD (pH = 5.5): -0.52837545
• LogD (pH = 7.4): 0.39041123
• Log P: 2.4620085
• 摩尔折射率: 54.9722 cm^3
• 极化性: 21.605932 Å^3
• 极化表面积: 35.25 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 2.17
• LOG S: -2.52
• 溶解度: 5.38e-01 g/l

分子性质

理化性质

• 溶解度: 8.25 mg/mL
• 疏水性(logP): 2.1; 2.569

药理学性质

• 给药途径: Oral, IV
• 生物利用度: 90%
• 排泄: Renal (10%)
• 半衰期: 10-12 hours
• 代谢: Hepatic (CYP2D6 and 1A2- mediated)
• 蛋白结合率: 50-60%
• 法定药品分级: POM (UK)
• 妊娠期药物分类: B1 (Australia); C (US)

产品相关信息

• 纯度: 95%

详细说明

DrugBank - DB00379

• Drug Groups: approved
• Description: Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. [PubChem]
• Indication: For the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation.
• Pharmacology: Mexiletine is a local anesthetic, antiarrhythmic agent (Class Ib), structurally similar to lidocaine, but orally active. Mexiletine has fast onset and offset kinetics, meaning that they have little or no effect at slower heart rates, and more effects at faster heart rates. It shortens the action potential duration, reduces refractoriness, and decreases Vmax in partially depolarized cells with fast response action potentials. Mexiletine either does not change the action potential duration, or decreases the action potential duration.
• Toxicity: Symptoms of overdose include nausea, hypotension, sinus bradycardia, paresthesia, seizures, bundle branch block, AV heart block, asystole, ventricular tachyarrythmia, including ventricular fibrillation, cardiovascular collapse, and coma.
• Affected Organisms: Humans and other mammals
• Biotransformation: Primarily hepatic (85%) via CYP2D6 and CYP1A2 (primarily CYP2D6).
• Absorption: Well absorbed (bioavailability 90%) from the gastrointenstinal tract.
• Half Life: 10-12 hours
• Protein Binding: 50-60%
• Elimination: Approximately 10% is excreted unchanged by the kidney. The urinary excretion of N-methylmexiletine in man is less than 0.5%.
• Distribution: * 5 to 7 L/lg
• External Links: Wikipedia; RxList; PDRhealth; Drugs.com